MacroGenics Inc. (MGNX) has reported updated results from its phase III study of Margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.
from RTT - Biotech http://bit.ly/2EcM28K
via IFTTT
No comments:
Post a Comment